Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of pancreas * Locally advanced or metastatic unresectable disease Exclusion Criteria: * No prior anti cancer chemotherapy, radiotherapy (except palliative \>4 weeks prior to entry, endocrine or immunotherapy or use of other investigational agents;